Trial · NCT03304379
Adverse events430
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 430
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Nervous system disorders | Placebo | 48 | 309 | 113 |
| other | Headache | Nervous system disorders | NSAIDs | 107 | 609 | 210 |
| other | Headache | Nervous system disorders | Fasinumab 1mg Q4W | 95 | 609 | 224 |
| other | Headache | Nervous system disorders | Fasinumab 3mg Q4W | 2 | 58 | 2 |
| other | Headache | Nervous system disorders | Fasinumab 6mg Q8W | 2 | 59 | 2 |
| other | Urinary tract infection | Infections and infestations | Placebo | 25 | 309 | 29 |
| other | Urinary tract infection | Infections and infestations | NSAIDs | 35 | 609 | 39 |
| other | Urinary tract infection | Infections and infestations | Fasinumab 1mg Q4W | 50 | 609 | 57 |
| other | Urinary tract infection | Infections and infestations | Fasinumab 3mg Q4W | 1 | 58 | 1 |
| other | Urinary tract infection | Infections and infestations | Fasinumab 6mg Q8W | 2 | 59 | 2 |
| other | Nasopharyngitis | Infections and infestations | Placebo | 22 | 309 | 26 |
| other | Nasopharyngitis | Infections and infestations | NSAIDs | 38 | 609 | 44 |
| other | Nasopharyngitis | Infections and infestations | Fasinumab 1mg Q4W | 29 | 609 | 35 |
| other | Nasopharyngitis | Infections and infestations | Fasinumab 3mg Q4W | 2 | 58 | 2 |
| other | Nasopharyngitis | Infections and infestations | Fasinumab 6mg Q8W | 1 | 59 | 1 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Placebo | 36 | 309 | 53 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | NSAIDs | 78 | 609 | 102 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Fasinumab 1mg Q4W | 82 | 609 | 109 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Fasinumab 3mg Q4W | 4 | 58 | 7 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Fasinumab 6mg Q8W | 3 | 59 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03304379/events